Jefferies initiated coverage of Kodiak Sciences (KOD) with a Buy rating and $15 price target. Kodiak has three drugs in Phase 3 study for eye diseases, each with key readouts in 2026, including lead asset ‘101 with data expected in Q4 of 2026 to Q1 of 2027, the analyst tells investors. A nearer-term catalyst may come from competitor Roche’s (RHHBY) data expected soon at the AAO meeting, the analyst added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Kodiak Sciences announces new data from APEX study of KSI-101
- Kodiak Sciences price target raised to $7 from $4 at Barclays
- Kodiak Sciences upgraded to Neutral from Underweight at JPMorgan
- Kodiak Sciences Reports Q2 2025 Financial Results and Clinical Progress
- Kodiak Sciences reports Q2 EPS ($1.03), consensus ($1.05)